These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 39182000)

  • 1. lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry.
    Aldenhoven L; van Weezelenburg MAS; van den Berkmortel FWPJ; Servaas N; Janssen A; Vissers YLJ; van Haaren ERM; Beets GL; van Bastelaar J
    Target Oncol; 2024 Sep; 19(5):735-745. PubMed ID: 39182000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world outcomes of patients with resected stage III melanoma treated with adjuvant therapies.
    Dima D; Lopetegui-Lia N; Ogbue O; Osantowski B; Ullah F; Jia X; Song JM; Gastman B; Isaacs J; Kennedy LB; Funchain P
    Cancer Med; 2024 Jun; 13(12):e7257. PubMed ID: 39031560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
    Bhave P; Pallan L; Long GV; Menzies AM; Atkinson V; Cohen JV; Sullivan RJ; Chiarion-Sileni V; Nyakas M; Kahler K; Hauschild A; Plummer R; Trojaniello C; Ascierto PA; Zimmer L; Schadendorf D; Allayous C; Lebbe C; Maurichi A; Santinami M; Roy S; Robert C; Lesimple T; Patel S; Versluis JM; Blank CU; Khattak A; Van der Westhuizen A; Carlino MS; Shackleton M; Haydon A
    Br J Cancer; 2021 Feb; 124(3):574-580. PubMed ID: 33087895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.
    Bloem M; van Not OJ; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Blokx WAM; Boers-Sonderen MJ; Bonenkamp JJ; de Groot JB; Haanen JB; Hospers GAP; Kapiteijn EW; de Meza MM; Piersma D; van Rijn RS; Stevense-den Boer MAM; van der Veldt AAM; Vreugdenhil G; van den Eertwegh AJM; Suijkerbuijk KPM; Wouters MWJM
    Int J Cancer; 2024 Oct; 155(8):1455-1465. PubMed ID: 38922879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
    Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China.
    Zhong J; Sun W; Hu T; Wang C; Yan W; Luo Z; Liu X; Xu Y; Chen Y
    Cancer Med; 2023 May; 12(10):11475-11482. PubMed ID: 37016119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant treatment for melanoma in clinical practice - Trial versus reality.
    de Meza MM; Ismail RK; Rauwerdink D; van Not OJ; van Breeschoten J; Blokx WAM; de Boer A; van Dartel M; Hilarius DL; Ellebaek E; Bonenkamp HJ; Blank CU; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; Boers-Sonderen MJ; de Groot JWB; Haanen JB; Hospers GAP; Kapiteijn EW; Piersma D; van Rijn RS; van der Veldt AAM; Vreugdenhil A; Westgeest HM; van den Eertwegh AJM; Suijkerbuijk KPM; Wouters MWJM
    Eur J Cancer; 2021 Nov; 158():234-245. PubMed ID: 34600790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study.
    Lodde GC; Hassel J; Wulfken LM; Meier F; Mohr P; Kähler K; Hauschild A; Schilling B; Loquai C; Berking C; Hüning S; Eckardt J; Gutzmer R; Reinhardt L; Glutsch V; Nikfarjam U; Erdmann M; Beckmann CL; Stang A; Kowall B; Galetzka W; Roesch A; Ugurel S; Zimmer L; Schadendorf D; Forschner A; Livingstone E
    Eur J Cancer; 2023 Sep; 191():112957. PubMed ID: 37487400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant vemurafenib in resected, BRAF
    Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
    Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma.
    Arak H; Erkiliç S; Yaslikaya Ş; Eylemer Mocan E; Aktaş G; Özdemir M; Semiz HS; Kiliçkap S; Özalp FR; Sever ÖN; Akdağ G; Ağaoğlu AB; Özçelik M; Sari M; Arcagök M; Anik H; Yayla ŞB; Sever N; Açar FP; Bayrakçi İ; Turhal S; Ayhan M; Kuş T;
    J Immunother; 2024 Jun; 47(5):182-189. PubMed ID: 38333962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis.
    Lattanzi M; Han J; Moran U; Utter K; Tchack J; Sabado RL; Berman R; Shapiro R; Huang HH; Osman I; Bhardwaj N; Pavlick AC
    J Immunother Cancer; 2018 May; 6(1):38. PubMed ID: 29773080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment.
    El Sharouni MA; Laeijendecker AE; Suijkerbuijk KP; Witkamp AJ; Sigurdsson V; van Diest PJ; van Gils CH; Blokx WA
    Eur J Cancer; 2021 May; 149():105-113. PubMed ID: 33848712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with BRAF-Mutant Advanced/Metastatic Melanoma: Original Research on the Treatment Reality in Germany and Austria in the Era of Choice.
    Haferkamp S; Alter M; Debus D; Schilling B; Pinter A; Terheyden P; Utikal JS; Sachse MM; Haalck T; Wolf IH
    Adv Ther; 2020 Aug; 37(8):3619-3629. PubMed ID: 32638206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM
    Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective.
    Kähler KC; Gutzmer R; Angela Y; Livingstone E; Lodde G; Meiss F; Rafei-Shamsabadi DA; Weyer-Fahlbusch SS; Nashan D; Loquai C; Hassel JC; Sachse MMM; Maul LV; Heinzerling L; Heppt MV; Colapietro C; Rusch J; Blome C
    J Cancer Res Clin Oncol; 2024 May; 150(5):252. PubMed ID: 38743104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
    Corrie PG; Marshall A; Dunn JA; Middleton MR; Nathan PD; Gore M; Davidson N; Nicholson S; Kelly CG; Marples M; Danson SJ; Marshall E; Houston SJ; Board RE; Waterston AM; Nobes JP; Harries M; Kumar S; Young G; Lorigan P
    Lancet Oncol; 2014 May; 15(6):620-30. PubMed ID: 24745696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
    Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.
    Jochems A; Schouwenburg MG; Leeneman B; Franken MG; van den Eertwegh AJ; Haanen JB; Gelderblom H; Uyl-de Groot CA; Aarts MJ; van den Berkmortel FW; Blokx WA; Cardous-Ubbink MC; Groenewegen G; de Groot JW; Hospers GA; Kapiteijn E; Koornstra RH; Kruit WH; Louwman MW; Piersma D; van Rijn RS; Ten Tije AJ; Vreugdenhil G; Wouters MW; van der Hoeven JJ
    Eur J Cancer; 2017 Feb; 72():156-165. PubMed ID: 28030784
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.